Curis(CRIS) - 2025 Q3 - Quarterly Results

Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2025 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025. "We made good progress advancing our clinical stu ...